Pricing Log in Create free account
Saturday 17 October 2026 Export SUPN’s income statement to Excel — free account

Supernus Pharmaceuticals, Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 32.4%, EPS fell 352.5% and free cash flow fell 109.3%, each against the same quarter a year earlier.

37.88 1.69 −4.27%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
103×
Dividend yield
—
F-score
5/9
Altman Z
5.41
Beneish M
−2.54
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.88
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — 2 — 1 5 — — — — — — —
Insider Ownership 6.10%

Capital & Financial Ratios $m

Market Cap 2,300.00
Revenue 830.44
Net Income (109.89)
Free Cash Flow 18.33
Net Debt (372.07)
Current Ratio 2.08 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 103.00 (above 35: high)
P/S ratio 2.65
P/B ratio 2.13
Past 5Y EPS Growth —
This Y EPS Growth (21.64%) (below 0%: weak)
Next Y EPS Growth 69.82% (at or above 15%: strong)
Next Y revenue growth 23.21% (at or above 10%: strong)
Next 5Y EPS Growth 18.63% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 3.3×; over the ten years it ranged from 2.1× in 2020 to 8.8× in 2017.
P/S against its own 10 years 18.36%
10-year low 10-year high
P/B against its own 10 years 44.31%
10-year low 10-year high
EV/Sales against its own 10 years 19.76%
10-year low 10-year high
EV/FCF against its own 10 years 97.20%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 255 454 309 372
Receivables 144 142 188 212
Inventory 77 54 82 84
Other — — — —
493 686 644 723
2023 2024 2025 Q'26
Payables 80 76 108 108
ST’ Debt — — — —
Other 56 47 69 40
290 292 338 347

Compound Annual Growth %

10y 5y 3y
Sales 17.17% 6.68% 2.52%
Cash Flow 3.21% (19.31%) (26.01%)
Earnings 0.00% 0.00% 0.00%
Book Value 28.28% 7.35% 6.21%

Revenue $m

Mar Jun Sep Dec Year
’26 208 219 — — —
’25 150 165 192 212 719
’24 144 168 176 174 662
’23 154 136 154 164 608
’22 153 170 177 167 667
’21 131 141 148 159 580
’20 95 127 155 144 520
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 67 (5) — — —
’25 31 59 (62) 20 47
’24 38 36 54 44 172
’23 49 (19) 36 45 111
’22 4 71 14 28 117
’21 36 46 (4) 49 127
’20 9 92 6 32 138
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 67 (5) — — —
’25 30 58 (62) 19 46
’24 38 36 53 44 171
’23 49 (19) 36 45 111
’22 3 72 14 28 116
’21 34 46 (4) 49 125
’20 6 91 5 32 135
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (1.01) — — —
’25 (0.21) 0.40 (0.80) (0.07) (0.68)
’24 0.00 0.36 0.69 0.27 1.32
’23 0.29 (0.02) (0.29) 0.02 0.02
’22 0.43 0.14 0.03 0.43 1.04
’21 0.11 0.43 0.40 0.04 0.98
’20 0.40 0.65 0.74 0.57 2.36
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 9.51 23.10 30.05 19.35 13.12 23.15 24.95 21.99 25.53 29.16

Analyst estimates 2026–2028

Powerpack
High 27.10 50.05 61.25 43.05 27.55 34.50 38.40 42.09 39.37 57.65
People
People Employees 363 422 448 464 563 575 612 652 674 778
Revenue/emp, $m 0.59 0.72 0.91 0.85 0.92 1.01 1.09 0.93 0.98 0.92
Income, $m
Income, $m Revenue 215 302 409 393 520 580 667 608 662 719
Gross margin, % 94.43 94.97 96.24 95.76 89.92 87.05 86.93 86.21 88.23 89.63
EBT 50 101 140 147 169 73 61 3 98 (49)
EBT margin, % 23.43 33.29 34.28 37.55 32.41 12.62 9.10 0.46 14.79 (6.82)
Net income 91 57 111 113 127 53 61 1 74 (39)
Depreciation 3 8 17 18 32 51 91 85 82 90
Per share, $
Per share, $ Revenue 4.35 5.95 7.86 7.49 9.89 10.92 12.43 11.14 12.01 12.74
Earnings 1.84 1.13 2.13 2.16 2.41 1.01 1.13 0.02 1.34 (0.68)
Cash flow 1.35 2.26 2.48 2.73 2.63 2.39 2.18 2.04 3.12 0.84
Capex (0.41) (0.04) (0.02) (0.03) (0.07) (0.04) (0.01) (0.01) (0.01) (0.02)
Free cash flow 0.94 2.22 2.46 2.70 2.56 2.36 2.17 2.03 3.11 0.81
Book value 3.88 5.27 8.71 11.36 14.16 15.36 16.51 16.90 18.80 18.81
Shares, m 49 51 52 52 53 53 54 55 55 56
Valuation, ×
Valuation, × P/E 14.10 35.80 15.52 11.03 10.44 28.59 33.16 1,118.15 26.94 0.00
P/S 5.97 6.79 4.22 3.17 2.54 2.67 3.01 2.49 3.01 3.90
P/B 6.70 7.68 3.81 2.09 1.78 1.90 2.27 1.64 1.92 2.64
EV/Sales 5.57 6.33 4.16 3.18 2.44 2.75 3.54 2.86 3.05 4.14
EV/FCF 25.82 19.97 13.44 8.90 9.55 12.91 20.54 15.94 11.89 67.01
Cash, $m
Cash, $m Operating cash flow 67 115 129 143 138 127 117 111 172 47
Capex (20) (2) (1) (1) (4) (2) 0 (1) (1) (1)
Free cash flow 46 113 128 142 135 125 116 111 171 46
Balance, $m
Balance, $m Working capital 71 105 332 312 385 286 46 203 394 306
Total debt 4 22 329 345 362 379 36 — — —
Net debt (86) (118) (27) (2) (61) 40 (461) (255) (454) (309)
Shareholders’ equity 192 267 453 595 745 816 886 922 1,036 1,062
Returns, %
Returns, % ROA 36.62 15.61 15.83 10.58 9.53 3.35 3.79 0.09 5.58 (2.73)
ROIC 32.03 41.63 21.17 15.64 15.87 6.29 6.79 (0.49) 8.77 (5.17)
ROE 65.21 24.95 30.81 21.57 18.94 6.85 7.55 0.15 7.55 (3.68)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Supernus Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LQDA Liquidia Corporation $3.1B 21.9× 18.5× +1,842.73% (above 0%: growing) n/m +270.23% (above 0%: growing) 93.27% 49.81% Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.4B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
PBH Prestige Consumer Healthcare Inc. $2.3B 13.9× 10.3× +6.48% (above 0%: growing) −36.46% (below 0%: shrinking) −14.19% (below 0%: shrinking) 51.25% 19.77% Compare
SUPN Supernus Pharmaceuticals, Inc. $2.3B — (loss-making) 103× +32.40% (above 0%: growing) n/m −109.26% (below 0%: shrinking) 84.63% (26.46%)
PRGO Perrigo Company plc $2.3B — (loss-making) — (loss-making) −3.17% (below 0%: shrinking) n/m +18.37% (above 0%: growing) 30.69% 2.31% Compare
ALVO Alvotech $2.1B — (loss-making) 8.9× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.1B — (loss-making) — (loss-making) +33.61% (above 0%: growing) +1,450.00% (above 0%: growing) +153.22% (above 0%: growing) 98.24% 45.12% Compare
XERS Xeris Biopharma Holdings, Inc. $1.8B — (loss-making) 54.5× +28.74% (above 0%: growing) n/m +8,403.09% (above 0%: growing) 86.41% 5.62% Compare
ANIP ANI Pharmaceuticals, Inc. $1.7B 14.9× 14.5× +25.87% (above 0%: growing) +194.59% (above 0%: growing) −22.19% (below 0%: shrinking) 62.35% 15.21% Compare
Median of peers $2.2B 14.9× 14.5× +31.17% +194.59% +65.79% 61.63% 12.18%

All 86 Drug Manufacturers Specialty & Generic stocks →

Supernus Pharmaceuticals, Inc. (SUPN) key facts

  • Strength: Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024.
  • Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SUPN traded at $37.88, a market capitalization of $2.3 billion.
  • Return on equity was −3.68% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.41 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Supernus Pharmaceuticals, Inc. (SUPN) Latest News

4 Aug

Impact 5 ·

3 Aug

Impact 5 ·
Impact 5 ·
stockrow.com/SUPN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com